HC Wainwright Has Negative Outlook for VNDA Q1 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for Vanda Pharmaceuticals in a report issued on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.52) for the quarter, down from their previous estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at $0.22 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%.

Separately, StockNews.com began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA opened at $4.55 on Thursday. The business has a fifty day moving average of $4.60 and a 200-day moving average of $4.83. Vanda Pharmaceuticals has a twelve month low of $3.71 and a twelve month high of $6.75. The firm has a market cap of $265.36 million, a PE ratio of -14.22 and a beta of 0.74.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Quantinno Capital Management LP acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $48,000. China Universal Asset Management Co. Ltd. lifted its position in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,374 shares during the period. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $69,000. Zacks Investment Management acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $74,000. Finally, Intech Investment Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the third quarter worth approximately $84,000. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.